Status:
COMPLETED
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Lead Sponsor:
Medical University of South Carolina
Collaborating Sponsors:
Takeda
Conditions:
Transplant Complication
CMV
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV inf...
Detailed Description
Maribavir has been evaluated for the prevention of CMV infection in Phase II and Phase III trials within allogeneic stem cell transplant recipients. At 6-months post-transplant, the rates of CMV infec...
Eligibility Criteria
Inclusion
- Kidney transplant recipient at study institution
- =7 days of transplant
- Received at least one dose of rATG induction or patient is D+/R- CMV serostatus
Exclusion
- Age \<18 years at time of transplant
- Recipient of pancreas, liver, heart, lung transplant
- Recipient of investigational, non-FDA approved medication
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06034925
Start Date
November 6 2023
End Date
August 30 2025
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425